nodes	percent_of_prediction	percent_of_DWPC	metapath
Framycetin—Steatorrhoea—Azathioprine—systemic scleroderma	0.0798	0.144	CcSEcCtD
Framycetin—CXCR4—endothelium—systemic scleroderma	0.0745	0.265	CbGeAlD
Framycetin—CXCR4—blood vessel—systemic scleroderma	0.0687	0.244	CbGeAlD
Framycetin—Secondary infection—Mometasone—systemic scleroderma	0.0372	0.0669	CcSEcCtD
Framycetin—CXCR4—connective tissue—systemic scleroderma	0.0352	0.125	CbGeAlD
Framycetin—CXCR4—smooth muscle tissue—systemic scleroderma	0.0322	0.114	CbGeAlD
Framycetin—Sensitisation—Mometasone—systemic scleroderma	0.0306	0.0551	CcSEcCtD
Framycetin—Secondary infection—Azathioprine—systemic scleroderma	0.0285	0.0513	CcSEcCtD
Framycetin—CXCR4—digestive system—systemic scleroderma	0.0254	0.0904	CbGeAlD
Framycetin—CXCR4—Hematopoietic Stem Cell Differentiation—CSF1—systemic scleroderma	0.0254	0.156	CbGpPWpGaD
Framycetin—Impaired healing—Mometasone—systemic scleroderma	0.0253	0.0455	CcSEcCtD
Framycetin—CXCR4—tendon—systemic scleroderma	0.0242	0.086	CbGeAlD
Framycetin—Ulcerative keratitis—Mycophenolate mofetil—systemic scleroderma	0.0236	0.0424	CcSEcCtD
Framycetin—Malabsorption—Methotrexate—systemic scleroderma	0.0232	0.0418	CcSEcCtD
Framycetin—CXCR4—lung—systemic scleroderma	0.0213	0.0755	CbGeAlD
Framycetin—Nerve injury—Prednisone—systemic scleroderma	0.0185	0.0333	CcSEcCtD
Framycetin—Impaired healing—Mycophenolic acid—systemic scleroderma	0.0174	0.0314	CcSEcCtD
Framycetin—Ulcerative keratitis—Prednisone—systemic scleroderma	0.016	0.0288	CcSEcCtD
Framycetin—Cataract subcapsular—Prednisone—systemic scleroderma	0.0155	0.0278	CcSEcCtD
Framycetin—Glaucoma—Mometasone—systemic scleroderma	0.0145	0.0261	CcSEcCtD
Framycetin—Impaired healing—Mycophenolate mofetil—systemic scleroderma	0.0138	0.0248	CcSEcCtD
Framycetin—CXCR4—CXCR4-mediated signaling events—RHOB—systemic scleroderma	0.0136	0.0833	CbGpPWpGaD
Framycetin—CXCR4—Hematopoietic Stem Cell Differentiation—IL1A—systemic scleroderma	0.0125	0.0766	CbGpPWpGaD
Framycetin—CXCR4—CXCR4-mediated signaling events—CSK—systemic scleroderma	0.0124	0.0759	CbGpPWpGaD
Framycetin—Viral infection—Mometasone—systemic scleroderma	0.0121	0.0218	CcSEcCtD
Framycetin—CXCR4—CXCR4-mediated signaling events—CD247—systemic scleroderma	0.0116	0.0714	CbGpPWpGaD
Framycetin—CXCR4—CXCR4-mediated signaling events—BLK—systemic scleroderma	0.0108	0.066	CbGpPWpGaD
Framycetin—Swelling—Pentoxifylline—systemic scleroderma	0.0104	0.0187	CcSEcCtD
Framycetin—Impaired healing—Prednisone—systemic scleroderma	0.00933	0.0168	CcSEcCtD
Framycetin—CXCR4—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.0084	0.0516	CbGpPWpGaD
Framycetin—Viral infection—Mycophenolic acid—systemic scleroderma	0.00835	0.015	CcSEcCtD
Framycetin—Impaired healing—Methotrexate—systemic scleroderma	0.0078	0.014	CcSEcCtD
Framycetin—Viral infection—Lisinopril—systemic scleroderma	0.00752	0.0135	CcSEcCtD
Framycetin—CXCR4—Syndecan-4-mediated signaling events—MMP9—systemic scleroderma	0.00733	0.045	CbGpPWpGaD
Framycetin—CXCR4—Chemokine receptors bind chemokines—CCL2—systemic scleroderma	0.00655	0.0402	CbGpPWpGaD
Framycetin—CXCR4—Hematopoietic Stem Cell Differentiation—IL1B—systemic scleroderma	0.0065	0.0399	CbGpPWpGaD
Framycetin—Swelling—Mycophenolic acid—systemic scleroderma	0.00621	0.0112	CcSEcCtD
Framycetin—Erythema—Pentoxifylline—systemic scleroderma	0.00553	0.00996	CcSEcCtD
Framycetin—CXCR4—HIV Infection—CD247—systemic scleroderma	0.00546	0.0335	CbGpPWpGaD
Framycetin—Glaucoma—Prednisone—systemic scleroderma	0.00536	0.00965	CcSEcCtD
Framycetin—Anaphylactic shock—Pentoxifylline—systemic scleroderma	0.00452	0.00813	CcSEcCtD
Framycetin—Infection—Pentoxifylline—systemic scleroderma	0.00449	0.00808	CcSEcCtD
Framycetin—Viral infection—Prednisone—systemic scleroderma	0.00447	0.00804	CcSEcCtD
Framycetin—CXCR4—Cardiac Progenitor Differentiation—TGFB1—systemic scleroderma	0.00404	0.0248	CbGpPWpGaD
Framycetin—Anaphylactic shock—Mometasone—systemic scleroderma	0.0039	0.00701	CcSEcCtD
Framycetin—Infection—Mometasone—systemic scleroderma	0.00387	0.00697	CcSEcCtD
Framycetin—CXCR4—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.00361	0.0222	CbGpPWpGaD
Framycetin—Anaphylactic shock—Captopril—systemic scleroderma	0.00342	0.00616	CcSEcCtD
Framycetin—CXCR4—CXCR4-mediated signaling events—MMP9—systemic scleroderma	0.00339	0.0208	CbGpPWpGaD
Framycetin—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.00333	0.00599	CcSEcCtD
Framycetin—Pruritus—Pentoxifylline—systemic scleroderma	0.0032	0.00575	CcSEcCtD
Framycetin—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00309	0.00556	CcSEcCtD
Framycetin—Erythema—Lisinopril—systemic scleroderma	0.00297	0.00535	CcSEcCtD
Framycetin—Infection—Azathioprine—systemic scleroderma	0.00297	0.00534	CcSEcCtD
Framycetin—Vomiting—Pentoxifylline—systemic scleroderma	0.00287	0.00517	CcSEcCtD
Framycetin—Anaphylactic shock—Leflunomide—systemic scleroderma	0.00282	0.00508	CcSEcCtD
Framycetin—Infection—Leflunomide—systemic scleroderma	0.0028	0.00504	CcSEcCtD
Framycetin—Pruritus—Mometasone—systemic scleroderma	0.00276	0.00496	CcSEcCtD
Framycetin—Nausea—Pentoxifylline—systemic scleroderma	0.00268	0.00483	CcSEcCtD
Framycetin—Infection—Mycophenolic acid—systemic scleroderma	0.00267	0.00481	CcSEcCtD
Framycetin—Diarrhoea—Mometasone—systemic scleroderma	0.00267	0.0048	CcSEcCtD
Framycetin—Vomiting—Mometasone—systemic scleroderma	0.00248	0.00446	CcSEcCtD
Framycetin—CXCR4—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.00247	0.0151	CbGpPWpGaD
Framycetin—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00242	0.00436	CcSEcCtD
Framycetin—Pruritus—Captopril—systemic scleroderma	0.00242	0.00436	CcSEcCtD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.00242	0.0149	CbGpPWpGaD
Framycetin—Infection—Lisinopril—systemic scleroderma	0.00241	0.00433	CcSEcCtD
Framycetin—Diarrhoea—Captopril—systemic scleroderma	0.00234	0.00422	CcSEcCtD
Framycetin—Nausea—Mometasone—systemic scleroderma	0.00231	0.00417	CcSEcCtD
Framycetin—Hypersensitivity—Azathioprine—systemic scleroderma	0.0022	0.00396	CcSEcCtD
Framycetin—Vomiting—Captopril—systemic scleroderma	0.00218	0.00392	CcSEcCtD
Framycetin—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.00212	0.00382	CcSEcCtD
Framycetin—Infection—Mycophenolate mofetil—systemic scleroderma	0.00211	0.0038	CcSEcCtD
Framycetin—Hypersensitivity—Leflunomide—systemic scleroderma	0.00208	0.00374	CcSEcCtD
Framycetin—Diarrhoea—Azathioprine—systemic scleroderma	0.00204	0.00368	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—RHOB—systemic scleroderma	0.00204	0.0125	CbGpPWpGaD
Framycetin—Nausea—Captopril—systemic scleroderma	0.00203	0.00366	CcSEcCtD
Framycetin—CXCR4—Disease—SMAD7—systemic scleroderma	0.00202	0.0124	CbGpPWpGaD
Framycetin—Pruritus—Leflunomide—systemic scleroderma	0.002	0.00359	CcSEcCtD
Framycetin—Diarrhoea—Leflunomide—systemic scleroderma	0.00193	0.00347	CcSEcCtD
Framycetin—Pruritus—Mycophenolic acid—systemic scleroderma	0.0019	0.00343	CcSEcCtD
Framycetin—Vomiting—Azathioprine—systemic scleroderma	0.0019	0.00342	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—RHOB—systemic scleroderma	0.00185	0.0114	CbGpPWpGaD
Framycetin—CXCR4—Disease—TGFBI—systemic scleroderma	0.00185	0.0113	CbGpPWpGaD
Framycetin—CXCR4—GPCR ligand binding—EDN1—systemic scleroderma	0.00184	0.0113	CbGpPWpGaD
Framycetin—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00184	0.00331	CcSEcCtD
Framycetin—Vomiting—Leflunomide—systemic scleroderma	0.00179	0.00323	CcSEcCtD
Framycetin—Hypersensitivity—Lisinopril—systemic scleroderma	0.00179	0.00321	CcSEcCtD
Framycetin—Nausea—Azathioprine—systemic scleroderma	0.00177	0.00319	CcSEcCtD
Framycetin—Erythema—Prednisone—systemic scleroderma	0.00176	0.00318	CcSEcCtD
Framycetin—Pruritus—Lisinopril—systemic scleroderma	0.00172	0.00309	CcSEcCtD
Framycetin—Vomiting—Mycophenolic acid—systemic scleroderma	0.00171	0.00308	CcSEcCtD
Framycetin—Nausea—Leflunomide—systemic scleroderma	0.00168	0.00302	CcSEcCtD
Framycetin—Diarrhoea—Lisinopril—systemic scleroderma	0.00166	0.00299	CcSEcCtD
Framycetin—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.00165	0.0102	CbGpPWpGaD
Framycetin—Nausea—Mycophenolic acid—systemic scleroderma	0.0016	0.00288	CcSEcCtD
Framycetin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00156	0.00282	CcSEcCtD
Framycetin—Vomiting—Lisinopril—systemic scleroderma	0.00154	0.00277	CcSEcCtD
Framycetin—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.0015	0.0027	CcSEcCtD
Framycetin—Erythema—Methotrexate—systemic scleroderma	0.00147	0.00265	CcSEcCtD
Framycetin—CXCR4—Disease—HSPG2—systemic scleroderma	0.00147	0.00905	CbGpPWpGaD
Framycetin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00145	0.00262	CcSEcCtD
Framycetin—Nausea—Lisinopril—systemic scleroderma	0.00144	0.00259	CcSEcCtD
Framycetin—Anaphylactic shock—Prednisone—systemic scleroderma	0.00144	0.00259	CcSEcCtD
Framycetin—Infection—Prednisone—systemic scleroderma	0.00143	0.00257	CcSEcCtD
Framycetin—CXCR4—Disease—CSK—systemic scleroderma	0.00142	0.00874	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—SMAD7—systemic scleroderma	0.00141	0.00868	CbGpPWpGaD
Framycetin—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00135	0.00243	CcSEcCtD
Framycetin—CXCR4—Disease—CD247—systemic scleroderma	0.00134	0.00821	CbGpPWpGaD
Framycetin—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00126	0.00227	CcSEcCtD
Framycetin—CXCR4—GPCR ligand binding—CCL2—systemic scleroderma	0.00126	0.00773	CbGpPWpGaD
Framycetin—Anaphylactic shock—Methotrexate—systemic scleroderma	0.0012	0.00217	CcSEcCtD
Framycetin—Infection—Methotrexate—systemic scleroderma	0.0012	0.00215	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—RHOB—systemic scleroderma	0.00109	0.00672	CbGpPWpGaD
Framycetin—Hypersensitivity—Prednisone—systemic scleroderma	0.00106	0.00191	CcSEcCtD
Framycetin—CXCR4—GPCR downstream signaling—EDN1—systemic scleroderma	0.00104	0.00639	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—HSPG2—systemic scleroderma	0.00103	0.00634	CbGpPWpGaD
Framycetin—Pruritus—Prednisone—systemic scleroderma	0.00102	0.00183	CcSEcCtD
Framycetin—CXCR4—Signaling Pathways—CSK—systemic scleroderma	0.000996	0.00612	CbGpPWpGaD
Framycetin—Diarrhoea—Prednisone—systemic scleroderma	0.000985	0.00177	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—EDN1—systemic scleroderma	0.000945	0.00581	CbGpPWpGaD
Framycetin—Vomiting—Prednisone—systemic scleroderma	0.000915	0.00165	CcSEcCtD
Framycetin—Hypersensitivity—Methotrexate—systemic scleroderma	0.000886	0.0016	CcSEcCtD
Framycetin—Nausea—Prednisone—systemic scleroderma	0.000855	0.00154	CcSEcCtD
Framycetin—Pruritus—Methotrexate—systemic scleroderma	0.000851	0.00153	CcSEcCtD
Framycetin—Diarrhoea—Methotrexate—systemic scleroderma	0.000823	0.00148	CcSEcCtD
Framycetin—Vomiting—Methotrexate—systemic scleroderma	0.000765	0.00138	CcSEcCtD
Framycetin—Nausea—Methotrexate—systemic scleroderma	0.000715	0.00129	CcSEcCtD
Framycetin—CXCR4—Signaling by GPCR—CCL2—systemic scleroderma	0.000646	0.00397	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—EDN1—systemic scleroderma	0.000559	0.00343	CbGpPWpGaD
Framycetin—CXCR4—Disease—NOS3—systemic scleroderma	0.000486	0.00298	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—CCL2—systemic scleroderma	0.000382	0.00234	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—NOS3—systemic scleroderma	0.00034	0.00209	CbGpPWpGaD
Framycetin—CXCR4—Disease—TGFB1—systemic scleroderma	0.000321	0.00197	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—MMP9—systemic scleroderma	0.000273	0.00168	CbGpPWpGaD
Framycetin—CXCR4—Signaling Pathways—TGFB1—systemic scleroderma	0.000225	0.00138	CbGpPWpGaD
